Oxford Biomedica plc reiterated earnings guidance for the year 2024. For the year, the company expected total Group revenues of between £126 million and £134 million.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
334.3 GBX | +2.53% | +4.46% | +51.94% |
09/05 | Avon Protection wins UK MoD supply deal; Molten Ventures up | AN |
09/05 | Molten Ventures wins UK MoD supply contract | AN |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+51.94% | 414M | |
+9.46% | 115B | |
+12.78% | 107B | |
-13.55% | 22.31B | |
-3.46% | 21.6B | |
-4.84% | 18.23B | |
-38.57% | 17.62B | |
+7.65% | 14.26B | |
+35.04% | 12.37B | |
-26.45% | 8.28B |
- Stock Market
- Equities
- OXB Stock
- News Oxford Biomedica plc
- Oxford Biomedica plc Reiterates Earnings Guidance for the Year 2024